Inclusion Criteria:

          1. Male or female patients aged ≥19 years

          2. Histologically confirmed mantle cell lymphoma (MCL) meeting the following criteria:
             determined by histology and either expression of cyclin D1 (in association with CD20
             and CD5) or evidence of t(11;14) translocation (by cytogenetics, fluorescence in-situ
             hybridization, or polymerase chain reaction)

          3. In all patients, a paraffin-embedded biopsy tissue block or slides (preferably of
             lymph node origin or bone marrow) was sent to central laboratories (Diagnostic
             Cytology Laboratories or department of pathology) for confirmation of diagnosis of
             MCL.

          4. Stage II, III, or IV

          5. Patients who received RCHOP or VR-CAP induction chemotherapy for 6 cycles confirmed
             response as more than PR or PR after induction therapy and who are ineligible for
             transplantation. .

          6. No clinical evidence of central nervous system (CNS) involvement by lymphoma

          7. Patients must have measurable disease; CT scans at baseline are required to define the
             extent of measurable disease; the scans must be obtained within 6 weeks prior to
             registration; combined CT/PET scans may be used for the baseline and subsequent
             evaluations if accurate tumor measurements can be obtained from the CT component

          8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          9. Absolute neutrophil count (ANC) > 1,000 mm^3 (unless low count due to marrow
             involvement or splenomegaly)

         10. Platelets > 75,000 mm^3 (unless low counts due to marrow involvement or splenomegaly)

         11. Creatinine clearance of ≥ 30 mL/min

         12. Total bilirubin ≤ 1.5 x the upper limit of normal (may be up to 3.0 mg/dL if due to
             Gilbert's disease or due to liver involvement by lymphoma), alanine transaminase level
             ≤3 times the upper limit of normal; aspartate transaminase level ≤3 times the upper
             limit of normal

         13. Patients over the age of 45 must have a left ventricular ejection fraction (LVEF) of
             greater than 45% documented within 90 days prior to registration

         14. Female patients had to be post-menopausal for ≥1 year, surgically sterile, or
             practicing an effective method of birth control (as described in the protocol), and
             have a negative serum beta-human chorionic gonadotropin or urine pregnancy test at
             screening; they also had to agree to continue using birth control measures for ≥6
             months after terminating treatment. Male patients had to agree to use an acceptable
             method of contraception for the duration of the study.

        Exclusion Criteria:

          1. Female patients who are lactating or have a positive serum pregnancy test during the
             screening period.

          2. Grade 2 or higher baseline peripheral neuropathy

          3. Major surgery within 14 days before enrollment.

          4. Radiotherapy within 14 days before enrollment. If the involved field is small, 7 days
             will be considered a sufficient interval between treatment and administration of the
             ixazomib.

          5. Central nervous system involvement.

          6. Infection requiring systemic antibiotic therapy or other serious infection within 14
             days before study enrollment.

          7. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled
             hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure,
             unstable angina, or myocardial infarction within the past 6 months.

          8. Systemic treatment, within 14 days before the first dose of ixazomib, with strong
             CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin,
             phenobarbital), or use of St. John's wort.

          9. Active systemic infection requiring treatment, a known diagnosis of human HIV, or
             active hepatitis B (hepatitis B carriers were permitted)

         10. Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to this protocol.

         11. Known allergy to any of the study medications, their analogues, or excipients in the
             various formulations of any agent.

         12. Known gastrointestinal(GI) disease or GI procedure that could interfere with the oral
             absorption or tolerance of ixazomib including difficulty swallowing.

         13. Diagnosed or treated for another malignancy within 2 years before study enrollment or
             previously diagnosed with another malignancy and have any evidence of residual
             disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are
             not excluded if they have undergone complete resection.

         14. Patient has more than Grade 2 peripheral neuropathy on clinical examination during the
             screening period.

         15. Participation in other clinical trials, including those with other investigational
             agents not included in this trial, within 30 days of the start of this trial and
             throughout the duration of this trial.

         16. Patients that have previously been treated with ixazomib, or participated in a study
             with ixazomib whether treated with ixazomib or not.